Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP39: Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UCECCO’23 Copenhagen
Year: 2023
Authors: Ghosh, S.(1)*;Feagan, B.(2);Ott, E.(3);Gasink, C.(3);Marano, C.(4);Miao, Y.(4);Sandborn, W.(5);Danese, S.(6);Abreu, M.(7);Sands, B.(8);
(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)Western University and Alimentiv Inc., Gastroenterology, London, Canada;(3)Janssen, Scientific Affairs, Horsham, United States;(4)Janssen, Research & Development, Spring House, United States;(5)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(6)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(7)University of Miami, Miller School of Medicine, Miami, United States;(8)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
OP40: PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study ResultsECCO’23 Copenhagen
Year: 2023
Authors: B. Sands*(1), L. Peyrin-Biroulet(2), S. Danese(3), D.T. Rubin(4), S. Vermeire(5), O. Laurent(6), A. Luo(6), D. Nguyen(6), JD. Lu(6),A. Wiechowska-Kozlowska(7), J. Leszczyszyn(8), R. Kempinski(9), J. Kierkus(10), C. Ma(11), T. Ritter*(12), B.G. Feagan(13), S. Targan*(14)
(1)Icahn School of Medicine at Mount Sinai, New York, New York, USA, (2)Last Inserm U954 and CHU de Nancy, Lorraine University, Nancy, France, (3)Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, (4)University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA, (5)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, (6)Prometheus Biosciences, Inc., San Diego, CA, USA, (7)Endoscopy Unit, SONOMED Medical Center, Szczecin, Poland, (8)Department of Gastroenterology, Melita Medical, Wroclaw, Poland, (9)Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland, (10)Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland, (11)Alimentiv Inc., London, ON, Canada Division of Gastroenterology & Hepatology, Department of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, (12)GI Alliance, Southlake, Texas, USA, (13)Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada, (14)Division of Gastroenterology and Hepatology, Center for Inflammatory Bowel Diseases, Cedars-Sinai Medical Center, Los Angeles, CA,USA
P001: Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.ECCO’23 Copenhagen
Year: 2023
Authors: Santo, J.(1)*;Gineste, P.(1);Scherrer, D.(2);Nitcheu, J.(1);Ehrlich, H.(3);Sands, B.E.(4);Vermeire, S.(5);
(1)Abivax, Clinical Operations, Paris, France;(2)Abivax, Research and Development, Paris, France;(3)Abivax, Chief Executive Officer, Paris, France;(4)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(5)UZ Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P002: Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitisECCO’23 Copenhagen
Year: 2023
Authors: Bajaj, A.(1)*;Markandey, M.(1);Vuyyuru, S.(1);Mohta, S.(1);Singh, M.(1);Verma, M.(1);Kumar, S.(1);Kante, B.(1);Kumar, P.(1);Makharia, G.(1);Kedia, S.(1);Travis, S.(2);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(2)University of Oxford, The Kennedy Institute and Translational Gastroenterology Unit, Oxford OX2 7FY, United Kingdom;
P003: MicroRNAs as biomarkers in Inflammatory Bowel Disease unclassified (IBDU) patient samples may predict the development from IBDU to Crohn's Disease or Ulcerative ColitisECCO’23 Copenhagen
Year: 2023
Authors: Pallikkunnath James, J.(1)*;Riis, L.B.(1,2);Malham, M.(3,4);Høgdall, E.(1,2);Langholz, E.(2,5);Nielsen, B.S.(6);
(1)Herlev University Hospital, Department of Pathology, Herlev, Denmark;(2)University of Copenhagen, Institute for Clinical Medicine, Copenhagen, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre, The Pediatric Department, Hvidovre, Denmark;(4)University of Copenhagen, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults- Hvidovre Hospital, Hvidovre, Denmark;(5)Herlev University Hospital, Department of Gasteroenterology, Herlev, Denmark;(6)Bioneer A/S, Molecular Histology, Hørsholm, Denmark;
P004: Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flareECCO’23 Copenhagen
Year: 2023
Authors: Levhar, N.(1)*;Hadar, R.(1);Braun, T.(1);Efroni, G.(1);Abramovich, I.(2);Gottlieb, E.(2);Granot, M.(1);Sandra, N.(3);Selinger, L.(3);Picard, O.(3);Yavzori, M.(3);Lahat, A.(3);Eliakim, R.(3);Weiss, B.(1);Kopylov, U.(3);Ben-Horin, S.(3);Amir, A.(1);Haberman Ziv, Y.(1);